公开(公告)号：US08016783B2

公开(公告)日：2011-09-13

申请号：US11998969

申请日：2007-12-03

申请人： Joseph M. Pastore ,  Julio C. Spinelli ,  Helen L. Reeve ,  Jeffrey Ross ,  Rodney W. Salo ,  Allan Shuros

发明人： Joseph M. Pastore ,  Julio C. Spinelli ,  Helen L. Reeve ,  Jeffrey Ross ,  Rodney W. Salo ,  Allan Shuros

IPC分类号： A61M31/00

CPC分类号： A61M5/1723 ,  A61B5/0031 ,  A61B5/1107 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/4839 ,  A61M5/14244 ,  A61M5/14276 ,  A61M2205/3523 ,  A61N1/3627

摘要： A drug delivery system detects a cardiac condition indicative of a need for increasing a cardiac metabolic level and, in response, releases a drug into tissue or blood to shift a source of metabolically synthesized energy fueling cardiac contraction from fatty acid to glucose. One example of such a system includes an implantable device detecting an ischemia and a transdermal drug delivery device delivering a drug when an ischemic condition is detected. Another example of such a system includes one or more implantable devices detecting a predefined change in cardiac metabolic level and delivering a drug when the change is detected. Such systems are applied to treat, for example, patients suffering ischemia and/or heart failure and patients having suffered myocardial infarction.

摘要翻译： 药物递送系统检测指示需要增加心脏代谢水平的心脏状况，并且作为响应将药物释放到组织或血液中以将促进心脏收缩的代谢合成能量的来源从脂肪酸转移到葡萄糖。 这种系统的一个实例包括检测缺血的可植入装置和当检测到缺血状况时递送药物的透皮药物递送装置。 这种系统的另一个例子包括一个或多个可植入装置，用于检测心脏代谢水平的预定变化并在检测到变化时递送药物。 这种系统被应用于治疗例如患有缺血和/或心力衰竭的患者和患有心肌梗塞的患者。

公开(公告)号：US07320675B2

公开(公告)日：2008-01-22

申请号：US10645823

申请日：2003-08-21

申请人： Joseph M. Pastore ,  Julio C. Spinelli ,  Helen L. Reeve ,  Jeffrey Ross ,  Rodney W. Salo ,  Allan Shuros

发明人： Joseph M. Pastore ,  Julio C. Spinelli ,  Helen L. Reeve ,  Jeffrey Ross ,  Rodney W. Salo ,  Allan Shuros

IPC分类号： A61M31/00

CPC分类号： A61M5/1723 ,  A61B5/0031 ,  A61B5/1107 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/4839 ,  A61M5/14244 ,  A61M5/14276 ,  A61M2205/3523 ,  A61N1/3627

摘要： A drug delivery system detects a cardiac condition indicative of a need for increasing a cardiac metabolic level and, in response, releases a drug into tissue or blood to shift a source of metabolically synthesized energy fueling cardiac contraction from fatty acid to glucose. One example of such a system includes an implantable device detecting an ischemia and a transdermal drug delivery device delivering a drug when an ischemic condition is detected. Another example of such a system includes one or more implantable devices detecting a predefined change in cardiac metabolic level and delivering a drug when the change is detected. Such systems are applied to treat, for example, patients suffering ischemia and/or heart failure and patients having suffered myocardial infarction.

公开(公告)号：US07668594B2

公开(公告)日：2010-02-23

申请号：US11207251

申请日：2005-08-19

申请人： Marina Brockway ,  Joseph M. Pastore ,  Yi Zhang ,  Carlos Ricci ,  Allan Shuros ,  Rodney W. Salo

发明人： Marina Brockway ,  Joseph M. Pastore ,  Yi Zhang ,  Carlos Ricci ,  Allan Shuros ,  Rodney W. Salo

IPC分类号： A61N1/368 ,  A61N1/08

CPC分类号： A61N1/36585 ,  A61N1/056 ,  A61N1/36114 ,  A61N1/3627 ,  A61N1/36521 ,  A61N1/36557

摘要： An implantable cardiac rhythm management (CRM) device delivers a chronic therapy while detecting an ischemic state. When the ischemic state indicates the occurrence of an ischemic event, the implantable CRM device delivers a post-ischemia therapy. The post-ischemia therapy and the chronic therapy are adjusted using feedback control with the ischemic state and parameters indicative of the effectiveness of the post-ischemic therapy and the effectiveness of the chronic therapy as inputs.

摘要翻译： 植入式心律管理（CRM）装置在检测缺血状态时进行慢性治疗。 当缺血状态表明发生缺血事件时，可植入的CRM装置传递缺血后的治疗。 使用具有缺血状态的反馈控制和指示缺血后治疗的有效性和作为输入的慢性治疗的有效性的参数来调整局部后缺血治疗和慢性治疗。

公开(公告)号：US20100121391A1

公开(公告)日：2010-05-13

申请号：US12689016

申请日：2010-01-18

申请人： Marina Brockway ,  Joseph M. Pastore ,  Yi Zhang ,  Carlos Ricci ,  Allan Shuros ,  Rodney W. Salo

发明人： Marina Brockway ,  Joseph M. Pastore ,  Yi Zhang ,  Carlos Ricci ,  Allan Shuros ,  Rodney W. Salo

IPC分类号： A61N1/365 ,  A61M37/00

CPC分类号： A61N1/36585 ,  A61N1/056 ,  A61N1/36114 ,  A61N1/3627 ,  A61N1/36521 ,  A61N1/36557

摘要： An implantable cardiac rhythm management (CRM) device delivers a chronic therapy while detecting an ischemic state. When the ischemic state indicates the occurrence of an ischemic event, the implantable CRM device delivers a post-ischemia therapy. The post-ischemia therapy and the chronic therapy are adjusted using feedback control with the ischemic state and parameters indicative of the effectiveness of the post-ischemic therapy and the effectiveness of the chronic therapy as inputs.

摘要翻译： 植入式心律管理（CRM）装置在检测缺血状态时进行慢性治疗。 当缺血状态表明发生缺血事件时，可植入的CRM装置传递缺血后的治疗。 使用具有缺血状态的反馈控制和指示缺血后治疗的有效性和作为输入的慢性治疗的有效性的参数来调整局部后缺血治疗和慢性治疗。

公开(公告)号：US20110230928A1

公开(公告)日：2011-09-22

申请号：US13113706

申请日：2011-05-23

申请人： Allan Shuros ,  Tamara Colette Baynham ,  Jihong Qu ,  Joseph M. Pastore ,  Andrew P. Kramer ,  Frits W. Prinzen ,  Ward Y. R. Vanagt ,  Richard N. Cornelussen

发明人： Allan Shuros ,  Tamara Colette Baynham ,  Jihong Qu ,  Joseph M. Pastore ,  Andrew P. Kramer ,  Frits W. Prinzen ,  Ward Y. R. Vanagt ,  Richard N. Cornelussen

IPC分类号： A61N1/365 ,  A61N1/362

CPC分类号： A61N1/362 ,  A61B17/22 ,  A61B18/1492 ,  A61B2017/22001 ,  A61B2018/00214 ,  A61B2018/0041 ,  A61B2018/00422 ,  A61N1/056 ,  A61N1/3625 ,  A61N5/1001 ,  A61N2001/0585

摘要： Cardiac protection pacing is applied to prevent or reduce cardiac injury and/or occurrences of arrhythmia associated with an ischemic event including the occlusion of a blood vessel during a revascularization procedure. Pacing pulses are generated from a pacemaker and delivered through one or more pacing electrodes incorporated onto a percutaneous transluminal vascular intervention (PTVI) device used in the revascularization procedure. The pacemaker generates the pacing pulses according to a predetermined cardiac protection pacing sequence before, during, and/or after the ischemic event.

摘要翻译： 应用心脏保护起搏来预防或减少与血管重建手术期间血管闭塞的缺血事件相关的心律失常和/或发生的心律不齐。 起搏脉冲从起搏器产生，并通过一个或多个起搏电极产生，并通过并入到血运重建术中使用的经皮腔内血管介入（PTVI）装置上。 起搏器根据在缺血事件之前，期间和/或之后的预定心脏保护起搏序列产生起搏脉冲。

公开(公告)号：US07962208B2

公开(公告)日：2011-06-14

申请号：US11113828

申请日：2005-04-25

申请人： Allan Shuros ,  Tamara Colette Baynham ,  Jihong Qu ,  Joseph M. Pastore ,  Andrew P. Kramer ,  Frits W. Prinzen ,  Ward Y. R. Vanagt ,  Richard N. Cornelussen

发明人： Allan Shuros ,  Tamara Colette Baynham ,  Jihong Qu ,  Joseph M. Pastore ,  Andrew P. Kramer ,  Frits W. Prinzen ,  Ward Y. R. Vanagt ,  Richard N. Cornelussen

IPC分类号： A61N1/08

CPC分类号： A61N1/362 ,  A61B17/22 ,  A61B18/1492 ,  A61B2017/22001 ,  A61B2018/00214 ,  A61B2018/0041 ,  A61B2018/00422 ,  A61N1/056 ,  A61N1/3625 ,  A61N5/1001 ,  A61N2001/0585

摘要： Cardiac protection pacing is applied to prevent or reduce cardiac injury and/or occurrences of arrhythmia associated with an ischemic event including the occlusion of a blood vessel during a revascularization procedure. Pacing pulses are generated from a pacemaker and delivered through one or more pacing electrodes incorporated onto a percutaneous transluminal vascular intervention (PTVI) device used in the revascularization procedure. The pacemaker generates the pacing pulses according to a predetermined cardiac protection pacing sequence before, during, and/or after the ischemic event.

摘要翻译： 应用心脏保护起搏来预防或减少与血管重建手术期间血管闭塞的缺血事件相关的心律失常和/或发生的心律不齐。 起搏脉冲从起搏器产生，并通过一个或多个起搏电极产生，并通过并入到血运重建术中使用的经皮腔内血管介入（PTVI）装置上。 起搏器根据在缺血事件之前，期间和/或之后的预定心脏保护起搏序列产生起搏脉冲。

公开(公告)号：US20080091138A1

公开(公告)日：2008-04-17

申请号：US11998969

申请日：2007-12-03

申请人： Joseph Pastore ,  Julio Spinelli ,  Helen Reeve ,  Jeffrey Ross ,  Rodney Salo ,  Allan Shuros

发明人： Joseph Pastore ,  Julio Spinelli ,  Helen Reeve ,  Jeffrey Ross ,  Rodney Salo ,  Allan Shuros

IPC分类号： A61M31/00

CPC分类号： A61M5/1723 ,  A61B5/0031 ,  A61B5/1107 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/4839 ,  A61M5/14244 ,  A61M5/14276 ,  A61M2205/3523 ,  A61N1/3627

摘要： A drug delivery system detects a cardiac condition indicative of a need for increasing a cardiac metabolic level and, in response, releases a drug into tissue or blood to shift a source of metabolically synthesized energy fueling cardiac contraction from fatty acid to glucose. One example of such a system includes an implantable device detecting an ischemia and a transdermal drug delivery device delivering a drug when an ischemic condition is detected. Another example of such a system includes one or more implantable devices detecting a predefined change in cardiac metabolic level and delivering a drug when the change is detected. Such systems are applied to treat, for example, patients suffering ischemia and/or heart failure and patients having suffered myocardial infarction.

摘要翻译： 药物递送系统检测指示需要增加心脏代谢水平的心脏状况，并且作为响应将药物释放到组织或血液中以将促进心脏收缩的代谢合成能量的来源从脂肪酸转移到葡萄糖。 这种系统的一个实例包括检测缺血的可植入装置和当检测到缺血状况时递送药物的透皮药物递送装置。 这种系统的另一个例子包括一个或多个可植入装置，用于检测心脏代谢水平的预定变化并在检测到变化时递送药物。 这种系统被应用于治疗例如患有缺血和/或心力衰竭的患者和患有心肌梗塞的患者。

公开(公告)号：US20050043675A1

公开(公告)日：2005-02-24

申请号：US10645823

申请日：2003-08-21

申请人： Joseph Pastore ,  Julio Spinelli ,  Helen Reeve ,  Jeffrey Ross ,  Rodney Salo ,  Allan Shuros

发明人： Joseph Pastore ,  Julio Spinelli ,  Helen Reeve ,  Jeffrey Ross ,  Rodney Salo ,  Allan Shuros

IPC分类号： A61B5/00 ,  A61B5/11 ,  A61M5/142 ,  A61M5/172 ,  A61M31/00 ,  A61N1/362

CPC分类号： A61M5/1723 ,  A61B5/0031 ,  A61B5/1107 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/4839 ,  A61M5/14244 ,  A61M5/14276 ,  A61M2205/3523 ,  A61N1/3627

摘要： A drug delivery system detects a cardiac condition indicative of a need for increasing a cardiac metabolic level and, in response, releases a drug into tissue or blood to shift a source of metabolically synthesized energy fueling cardiac contraction from fatty acid to glucose. One example of such a system includes an implantable device detecting an ischemia and a transdermal drug delivery device delivering a drug when an ischemic condition is detected. Another example of such a system includes one or more implantable devices detecting a predefined change in cardiac metabolic level and delivering a drug when the change is detected. Such systems are applied to treat, for example, patients suffering ischemia and/or heart failure and patients having suffered myocardial infarction.

摘要翻译： 药物递送系统检测指示需要增加心脏代谢水平的心脏状况，并且作为响应将药物释放到组织或血液中以将促进心脏收缩的代谢合成能量的来源从脂肪酸转移到葡萄糖。 这种系统的一个实例包括检测缺血的可植入装置和当检测到缺血状况时递送药物的透皮药物递送装置。 这种系统的另一个例子包括一个或多个可植入装置，用于检测心脏代谢水平的预定变化并在检测到变化时递送药物。 这种系统被应用于治疗例如患有缺血和/或心力衰竭的患者和患有心肌梗塞的患者。

公开(公告)号：US20070088214A1

公开(公告)日：2007-04-19

申请号：US11250928

申请日：2005-10-14

申请人： Allan Shuros ,  Rodney Salo ,  Michael Kane

发明人： Allan Shuros ,  Rodney Salo ,  Michael Kane

IPC分类号： A61B8/00

CPC分类号： A61B8/065 ,  A61B5/076 ,  A61B5/1076 ,  A61B5/6876 ,  A61B5/6884 ,  A61B8/02 ,  A61B8/06 ,  A61B8/12 ,  A61B8/4483

摘要： An ultrasonic implantable device includes an ultrasonic sensor having a plurality of transducers. The sensor is configured for mounting to a vessel wall. A first of the transducers directs sound waves in a direction at least partially upstream or downstream in the vessel. A second of the transducers directs sound waves in a radial direction through an interior of the vessel against a sidewall of the vessel. The sensor monitors a change in frequency of the sound waves from the first transducer to determine a fluid velocity in the vessel. The sensor also monitors a reflection time of the sound waves from the second transducer that return from the sidewall to determine an internal diameter of the vessel. The determined fluid velocity and vessel diameter can be used to determine a volumetric flow rate of the fluid in the vessel.

摘要翻译： 超声波可植入装置包括具有多个换能器的超声波传感器。 传感器被配置为安装到血管壁。 换能器中的第一个将声波沿至少部分在容器的上游或下游的方向引导。 传感器中的第二个将声波沿径向引导通过容器的内部抵靠容器的侧壁。 传感器监测来自第一换能器的声波的频率变化以确定容器中的流体速度。 传感器还监测来自第二换能器的声波的反射时间，其从侧壁返回以确定容器的内径。 确定的流体速度和容器直径可用于确定容器中流体的体积流量。

公开(公告)号：US20060173505A1

公开(公告)日：2006-08-03

申请号：US11116955

申请日：2005-04-28

申请人： Rodney Salo ,  Allan Shuros ,  Joseph Pastore ,  Qingsheng Zhu

发明人： Rodney Salo ,  Allan Shuros ,  Joseph Pastore ,  Qingsheng Zhu

IPC分类号： A61N1/362

CPC分类号： A61N1/3627 ,  A61N1/3682 ,  A61N1/3684

摘要： A method and apparatus are disclosed for treating mitral or tricuspid regurgitation with electrical stimulation. By providing pacing stimulation to a selected region of the left ventricle, such as one in proximity to the mitral valve apparatus or papillary muscles in a manner that pre-excites the region during early ventricular systole, a beneficial effect is obtained which can prevent or reduce the extent of mitral regurgitation.

摘要翻译： 公开了一种用于用电刺激治疗二尖瓣或三尖瓣反流的方法和装置。 通过在左心室的选定区域（例如在二尖瓣装置或乳头肌附近的区域）以在早期心室收缩期间预激活该区域的方式提供起搏刺激，可以获得有益效果，其可以预防或减少 二尖瓣反流的程度。